非甾体抗炎药对中轴型脊柱关节炎放射学脊柱进展的影响:10年起始队列结果
基于德国GESPIC起始队列252例中轴型脊柱关节炎患者(139例nr-axSpA、113例r-axSpA),分析NSAID摄入对mSASSS两年间期进展的影响。NSAID摄入评分每增加10分与放射学进展减缓相关(β=-0.052,95%CI:-0.097至-0.007),在r-axSpA中最明显(β=-0.077,95%CI:-0.152至-0.003)。
要点
- NSAID摄入评分每增加10分与mSASSS进展减缓相关(β=-0.052)
- 该减缓效应在r-axSpA患者中最明显(β=-0.077)
- COX2i与ns-NSAIDs的点估计分别为-0.061和-0.045,差异无统计学意义
核心结论
- 研究提示较高NSAID摄入,尤其是COX2i,对减缓axSpA放射学进展有益。
- 这些发现可能有助于治疗策略制定,尤其在r-axSpA中,但nr-axSpA仍需进一步研究。
研究设计与样本
- 利用德国脊柱关节炎起始队列(GESPIC)数据,分析252例axSpA患者(139例nr-axSpA、113例r-axSpA),均有至少两套脊柱X线片。
- 结局为每两年间期mSASSS的进展,采用广义估计方程拟合序贯条件均值模型,调整纵向重复暴露和时间依赖混杂因素。
- 报告NSAID摄入评分每增加10分对应mSASSS进展的β系数及95%CI。
主要发现
- 基线时201例(80.0%)患者接受NSAID治疗,其中46例(18%)使用COX2i、156例(62%)使用ns-NSAIDs,平均总NSAID摄入评分为38.3±35.5。
- NSAID摄入评分每增加10分与放射学进展减缓相关(β=-0.052,95%CI:-0.097至-0.007)。
- 该效应在r-axSpA患者中最明显(β=-0.077,95%CI:-0.152至-0.003)。
- 在所有axSpA患者中,COX2i与ns-NSAIDs相比点估计略低但无统计学显著性(β分别为-0.061和-0.045)。
临床怎么用
- 研究结果提示较高NSAID摄入可能减缓axSpA放射学进展,尤其COX2i,可能有助于治疗策略制定。
- 在r-axSpA中该效应最明显,nr-axSpA仍需进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to investigate the impact of nonsteroidal anti-inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX-2 inhibitors [COX2i] and nonselective NSAIDs [ns-NSAIDs]) and disease subgroups (radiographic [r-axSpA] and nonradiographic [nr-axSpA]). METHODS: Leveraging data from the German Spondyloarthritis Inception Cohort (GESPIC), we conducted analyses on 252 patients with axSpA (139 with nr-axSpA and 113 with r-axSpA), who had minimum two sets of spinal radiographs. The outcome was progression in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in two-year intervals. We fitted sequential conditional mean models by using generalized estimating equations and adjusting for longitudinal repeated measures of exposure and time-dependent confounders. We report β-coefficients with 95% confidence intervals (CIs) for outcomes reflecting the progression in mSASSS per 10-point increase in NSAID intake score. RESULTS: At baseline, 201 (80.0%) patients were under NSAID treatment, with 46 (18%) taking COX2i and 156 (62%) taking ns-NSAIDs, and mean total NSAID intake score was 38.3 ± 35.5. A 10-point increase in NSAID intake score was associated with retardation of radiographic progression (β = -0.052, 95% CI: -0.097 to -0.007), with this effect being most pronounced in patients with r-axSpA (β = -0.077, 95% CI: -0.152 to -0.003). COX2i showed a slightly lower point estimate (although not statistically significant) in progression compared to ns-NSAIDs among all patients with axSpA (β = -0.061 and -0.045, respectively). CONCLUSION: Our findings suggest a beneficial effect of higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA. These findings may help inform therapeutic strategies, particularly in r-axSpA, although further research is needed for nr-axSpA.
引用
- Torgutalp M, Rios Rodriguez V, Proft F, et al. The Impact of Nonsteroidal Anti-Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10-Year Results From an Inception Cohort. Arthritis Rheumatol. 2026. PMID: 41310944. doi:10.1002/art.43447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。